These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 27521836)

  • 21. The temporal impact of erythropoietin administration on mitochondrial function and dynamics in cardiac ischemia/reperfusion injury.
    Benjanuwattra J; Apaijai N; Chunchai T; Singhanat K; Arunsak B; Intachai K; Chattipakorn SC; Chattipakorn N
    Exp Mol Pathol; 2022 Aug; 127():104802. PubMed ID: 35679888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening.
    D'Souza SP; Yellon DM; Martin C; Schulz R; Heusch G; Onody A; Ferdinandy P; Baxter GF
    Am J Physiol Heart Circ Physiol; 2003 May; 284(5):H1592-600. PubMed ID: 12521930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain natriuretic peptide limits myocardial infarct size dependent of nitric oxide synthase in rats.
    Ren B; Shen Y; Shao H; Qian J; Wu H; Jing H
    Clin Chim Acta; 2007 Feb; 377(1-2):83-7. PubMed ID: 17026975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Speckle tracking imaging improves in vivo assessment of EPO-induced myocardial salvage early after ischemia-reperfusion in rats.
    Treguer F; Donal E; Tamareille S; Ghaboura N; Derumeaux G; Furber A; Prunier F
    Am J Physiol Heart Circ Physiol; 2010 Jun; 298(6):H1679-86. PubMed ID: 20363897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts.
    Hirata A; Minamino T; Asanuma H; Sanada S; Fujita M; Tsukamoto O; Wakeno M; Myoishi M; Okada K; Koyama H; Komamura K; Takashima S; Shinozaki Y; Mori H; Tomoike H; Hori M; Kitakaze M
    Cardiovasc Drugs Ther; 2005 Jan; 19(1):33-40. PubMed ID: 15883754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Galanin/GalR1-3 system: A promising therapeutic target for myocardial ischemia/reperfusion injury.
    Palkeeva M; Studneva I; Molokoedov A; Serebryakova L; Veselova O; Ovchinnikov M; Sidorova M; Pisarenko O
    Biomed Pharmacother; 2019 Jan; 109():1556-1562. PubMed ID: 30551408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcription factor GATA-4 is involved in erythropoietin-induced cardioprotection against myocardial ischemia/reperfusion injury.
    Shan X; Xu X; Cao B; Wang Y; Guo L; Zhu Q; Li J; Que L; Chen Q; Ha T; Li C; Li Y
    Int J Cardiol; 2009 May; 134(3):384-92. PubMed ID: 18672303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of KR-33028, a novel Na+/H+ exchanger-1 inhibitor, on ischemia and reperfusion-induced myocardial infarction in rats and dogs.
    Oh KS; Seo HW; Yi KY; Lee S; Yoo SE; Lee BH
    Fundam Clin Pharmacol; 2007 Jun; 21(3):255-63. PubMed ID: 17521294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autophagosome formation is required for cardioprotection by chloramphenicol.
    Giricz Z; Varga ZV; Koncsos G; Nagy CT; Görbe A; Mentzer RM; Gottlieb RA; Ferdinandy P
    Life Sci; 2017 Oct; 186():11-16. PubMed ID: 28778689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappaB.
    Xu B; Dong GH; Liu H; Wang YQ; Wu HW; Jing H
    Ann Clin Lab Sci; 2005; 35(2):161-8. PubMed ID: 15943180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion.
    Lipsic E; van der Meer P; Henning RH; Suurmeijer AJ; Boddeus KM; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
    J Cardiovasc Pharmacol; 2004 Oct; 44(4):473-9. PubMed ID: 15454856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion.
    Toma C; Letts DP; Tanabe M; Gorcsan J; Counihan PJ
    J Mol Cell Cardiol; 2007 Aug; 43(2):130-6. PubMed ID: 17597149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quaternary ammonium salt of U50488H, a new κ-opioid receptor agonist, protects rat heart against ischemia/reperfusion injury.
    Wang Q; Sun Y; Li J; Xing W; Zhang S; Gu X; Feng N; Zhao L; Fan R; Wang Y; Yin W; Pei J
    Eur J Pharmacol; 2014 Aug; 737():177-84. PubMed ID: 24855042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardioprotective Effects of Mitochondria-Targeted Peptide SBT-20 in two Different Models of Rat Ischemia/Reperfusion.
    Dai W; Cheung E; Alleman RJ; Perry JB; Allen ME; Brown DA; Kloner RA
    Cardiovasc Drugs Ther; 2016 Dec; 30(6):559-566. PubMed ID: 27747447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretreatment with B-type natriuretic peptide protects the heart from ischemia-reperfusion injury by inhibiting myocardial apoptosis.
    Wu B; Jiang H; Lin R; Cui B; Wen H; Lu Z
    Tohoku J Exp Med; 2009 Oct; 219(2):107-14. PubMed ID: 19776527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury.
    Piuhola J; Kerkelä R; Keenan JI; Hampton MB; Richards AM; Pemberton CJ
    Clin Sci (Lond); 2008 Feb; 114(4):293-304. PubMed ID: 17919123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelin receptor antagonist BQ-123 ameliorates myocardial ischemic-reperfusion injury in rats: a hemodynamic, biochemical, histopathological and electron microscopic evidence.
    Goyal SN; Bharti S; Arora S; Golechha M; Arya DS
    Biomed Pharmacother; 2010 Nov; 64(9):639-46. PubMed ID: 20888175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II.
    Segawa D; Sjöquist PO; Wang QD; Gonon A; Rydén L
    J Cardiovasc Pharmacol; 2002 Sep; 40(3):339-45. PubMed ID: 12198319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardioprotection by farnesol: role of the mevalonate pathway.
    Szűcs G; Murlasits Z; Török S; Kocsis GF; Pálóczi J; Görbe A; Csont T; Csonka C; Ferdinandy P
    Cardiovasc Drugs Ther; 2013 Aug; 27(4):269-77. PubMed ID: 23673412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.
    Qian J; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):129-41. PubMed ID: 26861490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.